Sierra Oncology Inc. (SRRA) |
|
15.48 -0.15 (-0.96%)
|
02-14 16:00 |
|
Open: |
15.91 |
Pre. Close: |
15.63 |
|
High:
|
16.0113 |
Low:
|
15.13 |
|
Volume:
|
35,223 |
Market Cap:
|
161M |
|
|
|
|
Sierra Oncology Inc is a clinical-stage drug development company engaged in next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
16.026 - 16.114 |
16.114 - 16.187 |
|
Low:
|
14.924 - 15.03 |
15.03 - 15.118 |
|
Close:
|
15.317 - 15.482 |
15.482 - 15.619 |
|
Technical analysis |
as of: 2020-02-14 4:32:47 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 19.44 One year: 22.99 |
| Support: |
Support1: 11.73 Support2: 9.76 |
| Resistance: |
Resistance1: 16.64 Resistance2: 19.68 |
| Pivot: |
13.47  |
| Moving Average: |
MA(5): 15.25 MA(20): 13.69
MA(100): 13.67 MA(250): 30.43 |
| MACD: |
MACD(12,26): 0.19 Signal(9): -0.19 |
| Stochastic oscillator: |
%K(14,3): 81.52 %D(3): 81.20 |
| RSI: |
RSI(14): 56.35 |
| 52-week: |
High: 80.40 Low: 8.64 Change(%): -77.2 |
| Average Vol(K): |
3-Month: 7332 10-Days: 7684 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.SRRA has closed below upper band by 16.5%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
2020-02-11
The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
2020-02-06
Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1,…
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
